Insider transactions

Alan W Dunton

CIK 1304773 · Chief Exec Officer & President · last filed 2026-08-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$630.2K
Companies
6
Total Filings
124
Lifetime Open-Market Net
$3.59M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

PTN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
VICURON PHARMACEUTICALS INC
455 S GULPH ROAD SUITE 305
KING OF PRUSSIA, PA 19406
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PTN Director 13,382 $4.80 $64.2K $4.02M 33 2026-08-05
CRMD Director 70,703 $8.00 $565.6K -$338.3K 16 2026-01-27
OGEN Director 854 $0.37 $320 -$186.7K 28 2025-12-15
MNOV Director — $1.40 — $0 4 2010-06-15
PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Chief Exec Officer & President 240,865 — — $96.3K 8 2008-05-05
Adams Respiratory Therapeutics, Inc. (ARXT) Delisted Director 0 — — $0 7 2008-01-30

Recent Filings · Page 11 of 13

124 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2010-06-15 MNOV Grant (A) — $0 EDGAR
2009-06-17 — Grant (A) — $0
2009-06-15 MNOV Grant (A) — $0 EDGAR
2008-07-07 — Grant (A) — $0
2008-06-10 MNOV Grant (A) — $0 EDGAR
2008-05-05 PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Buy (P) +100,000 $46.2K EDGAR
2008-05-02 PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Grant (A) +100,000 $46.2K EDGAR
2008-02-14 PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Grant (A) +100,000 $0 EDGAR
2008-02-14 PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Grant (A) — $0 EDGAR
2008-01-30 Adams Respiratory Therapeutics, Inc. (ARXT) Delisted Disp (D) −1,623 -$97.4K EDGAR
Showing 101–110 of 124
Page 11 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.